Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges

219Citations
Citations of this article
275Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Autoimmune diseases are caused when immune cells act against self-protein. This biological self–non-self-discrimination phenomenon is controlled by a distinct group of lymphocytes known as regulatory T cells (Tregs), which are key inflammatory response regulators and play a pivotal role in immune tolerance and homeostasis. Treg-mediated robust immunosuppression provides self-tolerance and protection against autoimmune diseases. However, once this system fails to operate or poorly operate, it leads to an extreme situation where immune system reacts against self-antigens and destroys host organs, thus causing autoimmune diseases. Tregs can target both innate and adaptive immunity via modulating multiple immune cells such as neutrophils, monocytes, antigen-presenting cells, B cells, and T cells. This review highlights the Treg-mediated immunosuppression, role of several markers and their interplay during Treg development and differentiation, and advances in therapeutic aspects of Treg cells to reduce severity of autoimmunity-related conditions along with emphasizing limitations and challenges of their usages.

Cite

CITATION STYLE

APA

Goswami, T. K., Singh, M., Dhawan, M., Mitra, S., Emran, T. B., Rabaan, A. A., … Dhama, K. (2022). Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders–Advances and challenges. Human Vaccines and Immunotherapeutics. Taylor and Francis Ltd. https://doi.org/10.1080/21645515.2022.2035117

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free